News >

Emergence of Biosimilars Poised to Alleviate Financial Toxicity in Oncology

Ellie Leick
Published: Friday, Nov 15, 2019

Bradley G. Somer, MD, medical oncologist, senior partner of the Executive Cancer Council, and head of
Strategic Expansion/Development of West Cancer Center, and an associate professor in the Department of Hematology and Medical Oncology at the University of Tennessee Health Science Center, discussed the emergence of biosimilars in oncology

Bradley G. Somer, MD

The emergence of biosimilars in cancer care has the potential to relieve some of the financial burden related to drug costs, as well as increase sustainable growth within the field, explained Bradley G. Somer, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication